Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

98.25 -2.49 (-2.47%)

Streaming Delayed Price Updated: 3:55 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗

June 30, 2025

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Via Investor's Business Daily

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

June 30, 2025

Via ACCESS Newswire

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate

June 26, 2025

Via ACCESS Newswire

9 Analysts Assess Protagonist Therapeutics: What You Need To Know ↗

June 03, 2025

Via Benzinga

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

June 01, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025

May 21, 2025

Via ACCESS Newswire

PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) showing some interesting technicals. Here's why. ↗

May 15, 2025

Interesting Technical Analysis finding for PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX): Indications Suggest NASDAQ:PTGX Could Be on the Verge of a Breakout.

Via Chartmill

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study ↗

May 09, 2025

Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.

Via Benzinga

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting

May 09, 2025

Via ACCESS Newswire

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 06, 2025

Via ACCESS Newswire

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

April 23, 2025

Via ACCESS Newswire

Protagonist Therapeutics Reports Granting of Inducement Award

April 16, 2025

Via ACCESS Newswire

Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study ↗

April 10, 2025

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.

Via Benzinga

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

April 10, 2025

Via ACCESS Newswire

Does PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) align with Mark Minervini’s trading strategy? ↗

April 05, 2025

Should you consider PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) for high growth investing? A fundamental and technical analysis of (NASDAQ:PTGX).

Via Chartmill

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

March 18, 2025

Via ACCESS Newswire

D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? ↗

March 16, 2025

Mid-cap stocks were top performers last week. D-Wave, Protagonist, Veren, IonQ, Rigetti, Semtech, Orla Mining, and Hesai all saw significant gains.

Via Benzinga

Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 11, 2025

Via Benzinga

Keep an eye on the top gainers and losers in Monday's session. ↗

March 10, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.

Via Chartmill

Monday's session: top gainers and losers ↗

March 10, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

March 10, 2025

The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday ↗

March 10, 2025

Via Benzinga

Top movers in Monday's pre-market session ↗

March 10, 2025

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

Why Is Protagonist Therapeutics Stock Trading Higher On Monday? ↗

March 10, 2025

Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints.

Via Benzinga

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out ↗

March 10, 2025

The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment.

Via Investor's Business Daily

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

March 10, 2025

Via ACCESS Newswire

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

March 08, 2025

Via ACCESS Newswire

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer ↗

March 03, 2025

Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety results, earning Protagonist $25 million.

Via Benzinga

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

March 03, 2025

From Takeda Pharmaceutical Company Limited

Via Business Wire

PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) is a candidate for growth investors. Here's why. ↗

March 03, 2025

A fundamental analysis of (NASDAQ:PTGX): PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) showing high EPS and FCF growth while beating expectations

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.